Harrow Licenses Canadian Rights to Apotex For Five Branded Ophthalmic Pharmaceutical Products NASHVILLE, Tenn. and TORONTO, Ontario, Canada (

Licenses Canadian Rights to Apotex

For Five Branded Ophthalmic Pharmaceutical Products

Tenn. and TORONTO, Ontario, Canada (February 15, 2024) - Harrow, Inc. (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company,

and Apotex Inc. ("Apotex"), Canada's largest pharmaceutical company, today jointly announced an exclusive out-licensing

agreement under which Apotex will market and distribute VERKAZIA and over-the-counter (OTC) Cationorm

PLUS in the Canadian market, and concurrently, pursue market approval in Canada for VEVYE , IHEEZO , and

are pleased to enter the Canadian market through this partnership with Apotex, which has a proven track record of success serving Canadian

eyecare professionals and their patients," said Mark L. Baum, Chairman and Chief Executive Officer of Harrow. "This exclusive

agreement fulfills our commitment to access and availability of these five important ophthalmic pharmaceutical products, and we look

forward to working closely with our partners at Apotex over the coming years as they seek approval for VEVYE, IHEEZO and ZERVIATE in

the Canadian market."

are excited to partner with Harrow to provide access to an innovative branded line of ophthalmic products that complement our existing

portfolio," stated Allan Oberman, President and Chief Executive Officer of Apotex. "This alliance expands Apotex's

product offering in Canada to include innovative patented pharmaceutical medicines, aligned with our ongoing strategic focus to further

expand our innovative branded pharmaceutical therapeutic areas of focus in becoming a Canadian-based global health company."

these products strengthens our therapeutic line and provides Canadian patients with valuable new treatment options," adds Mike

Woolcock, Senior Vice President, Biosimilars & Specialty. "We look forward to collaborating with Harrow to expand this line

with VEVYE, IHEEZO, and ZERVIATE upon receiving market approval to improve the overall patient quality of life in this category."

the terms of the agreement, Apotex licensed exclusive rights and marketing authorizations of the following products in the Canadian market

for products, Apotex will pursue approval for in Canada:

Licenses Canadian Rights to Apotex For Five Branded Ophthalmic Pharmaceutical Products

Inc. is a Canadian-based global health company that produces high-quality, affordable and complex medicines for patients around the world,

with a strategic focus on becoming a Pan-Canadian Health Champion. Apotex has an integrated portfolio of generic and innovative branded

pharmaceutical products for global markets. Apotex employs almost 7,000 people worldwide in manufacturing, R&D, and commercial operations.

Apotex medicines are accessible to patients in more than 75 countries globally. Through vertical integration, Apotex is comprised of

multiple divisions and affiliates, including Apotex Inc., focused on generic and specialty innovative medicines in Canada and internationally,

Apotex Corp., an affiliate of Apotex Inc. which markets and sells products in the United States, and Apobiologix, a division of Apotex

Inc. focused on biosimilar development. For more information, visit: www.apotex.com

Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative

ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making

its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans

each year. For more information about Harrow, please visit harrow.com.

press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act

of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements."

Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may

cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties

that could cause actual results to differ from those predicted include, among others, risks related to: our ability to successfully implement

our business plan and commercialize our products in a timely manner or at all, obtain necessary approvals for products in Canada, recruit

and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of the licensing arrangements;

physician interest in and market acceptance of our products; competition from other pharmaceutical companies; general economic and business

conditions, including inflation and supply chain challenges; and regulatory and legal risks and uncertainties related to our operations

and the pharmaceutical business in general. These and additional risks and uncertainties are more fully described in Harrow's filings

with the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K and its Quarterly Reports

on Form 10-Q. Such documents may be read free of charge on the SEC's web site at sec.gov. Undue reliance should not be placed

on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation

to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect

the occurrence of unanticipated events.